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The use of left ventricular assist devices in treating patients with end-stage heart failure has increased signifi-
cantly in recent years, both as a bridge to transplantation and as destination therapy in those who are ineligible
for cardiac transplantation. This increase is based largely on the results of several recently completed clinical
trials with the new second-generation continuous-flow devices that showed significant improvements in survival,
functional capacity, and quality of life. Additional information on the use of the first- and second-generation left
ventricular assist devices has come from a recently released report spanning the years 2006 to 2009, from the
Interagency Registry for Mechanically Assisted Circulatory Support, a National Heart, Lung, and Blood Institute–
sponsored collaboration between the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid
Services, and the scientific community. The authors review the latest clinical trials and data from the registry,
with tight integration of the landmark molecular, cellular, and genomic research that accompanies the reverse
remodeling of the human heart in response to a left ventricular assist device and functional recovery that has
been reported in a subset of these patients. (J Am Coll Cardiol 2011;57:641–52) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.010Clinical Perspective
Currently, the average mortality from the time of diagnosis
of heart failure, regardless of whether there is preserved or
reduced systolic function, is 60% at 5 years, and this is
much higher when patients are in the most advanced stages
(1). Patients typically become progressively less responsive
to medical therapy and are left with limited options for
meaningful improvement in survival or functional capacity
and quality of life (2).
Cardiac transplantation is currently the most established
treatment for refractory heart failure (1). However, this
option is available to fewer than 2,300 patients per year,
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increase anticipated in the near future. The prevalence of
heart failure increases with age and affects an estimated 10%
of people over 70 years of age, which is the age that many
transplantation programs use as a cutoff for accepting
candidates. Importantly, the population over age 65 is expected
to double in the next 20 years. As a result, the use of left
ventricular assist devices (LVADs) in treating patients with
end-stage heart failure will increase significantly in the
coming years, both as a bridge to transplantation and as
destination therapy in those who are ineligible for cardiac
transplantation (3).
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LVAD Review: Clinical, Molecular, and Genomic February 8, 2011:641–52In 2009, the Centers for Medi-
care and Medicaid Services set a
mandate that patients receiving
ventricular assist devices be en-
tered into a national database,
the Interagency Registry for Me-
chanically Assisted Circulatory
Support (INTERMACS) (3).
INTERMACS is a National Heart,
Lung, and Blood Institute funded
collaboration between the Na-
tional Heart, Lung, and Blood
Institute, the U.S. Food and Drug
Administration, the Centers for
Medicare and Medicaid Services,
and the mechanical circulatory
support scientific community (3).
This registry has shown that pa-
tients with LVADs alone have
overall actuarial survival rates of
74% at 1 year and 55% at 2 years
(3). The primary cause of death in
the 1,092 primary LVAD patients
in INTERMACS from June 2006
through March 2009 was cardiac
failure, including right ventricular
ailure and ventricular tachycardia or ventricular fibrillation (3).
he secondary cause of death was infection (3).
At the inception of INTERMACS, the HeartMate XVE
ulsatile-flow pump (Thoratec Corporation, Pleasanton,
alifornia) was the only approved device for destination
herapy in the U.S. In April 2008, the HeartMate II
Thoratec Corporation), a continuous-flow LVAD, re-
eived Food and Drug Administration approval as a bridge
o transplantation based on the results of the clinical trial
4). Thus, the registry began tracking the evolution of
ontinuous-flow technology in addition to the original
ulsatile flow pumps (3). A recent randomized trial showed
hat patients receiving treatment with continuous-flow
VADs (HeartMate II) as destination therapy exhibited
ignificant improvement in the probability of stroke-free
urvival and device failure at 2 years compared with those
eceiving pulsatile LVADs (5). Both continuous-flow and
ulsatile devices significantly improved the quality of life
nd functional capacity (Thoratec HeartMate II Left Ven-
ricular Assist System [LVAS] for Destination Therapy;
CT00121485) (5). However, the survival outcomes with
he pulsatile device were nearly identical to those in patients
nrolled nearly 10 years earlier in the Randomized Evaluation
f Mechanical Assistance for the Treatment of Congestive
eart Failure for destination therapy patients, indicating little
rogress with that pump (6).
Clinical heart failure may present with changes referred
o as remodeling that include eccentric dilation of the
entricular chamber, a reduction in contractile function, and
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AGAT  arginine:glycine
amidinotransferase
ANP  atrial natriuretic
peptide
BNP  B-type natriuretic
peptide
Epac2  exchange protein
directly activated by cyclic
adenosine monophosphate
IGF  insulin growth factor
INTERMACS  Interagency
Registry for Mechanically
Assisted Circulatory
Support
LVAD  left ventricular
assist device
miRNA  micro–ribonucleic
acid
mRNA  messenger
ribonucleic acid
RNA  ribonucleic acidncreases in cardiac filling pressures and wall stress. Theselinical phenotypic changes of heart failure are paralleled by
ignificant histologic, cellular, and molecular changes in
ost structural and functional components of the myocyte,
ncluding alterations in myocyte geometry and size, progres-
ive interstitial fibrosis, up-regulation of cytokines and
nflammation, and changes in myosin isoforms, as well as
eductions in myocardial energetics, beta-receptor density,
nd calcium-handling proteins; this is otherwise described
s recapitulation of the fetal gene program. These cellular
nd molecular changes may arise from a response to changes
n volume, stretch, pressure, and inflammation that occur as
result of diet, additional environmental modifiers, and/or
enetic mutations. A progressive body of evidence has
hown a trend toward normalization of these perturbations,
r reverse remodeling, with LVAD support. However,
esponse to an LVAD is unique to each patient, suggesting
hat underlying factors are critical in the response to
herapy.
unctional Improvements in Myocytes
n Response to LVAD Unloading,
inked to Gene Expression Changes
ranslational research from human heart tissue before and
fter support with an LVAD has shown that myocytes in
nd-stage failing hearts have the capacity to remodel. These
hanges are accompanied by alterations in gene expression.
e summarize findings in the field that have led to
mportant steps forward in our understanding of the mo-
ecular changes and contractile properties of cardiac myo-
ytes before and after unloading with an LVAD.
There is evidence of early mechanical improvements in
ailing hearts treated with LVADs (7–15). These early
ndings were important in showing that the contractile
erformance of myocytes was partially recovered in response
o therapy with an LVAD. Myocyte contractile perfor-
ance was significantly greater in isolated myocytes from
ailing human hearts after LVAD support compared with
ailing human hearts without LVAD support in patients
ridged to transplantation (Table 1) (8). Improvements in
he magnitude of shortening were seen in isolated myocytes
fter LVAD support in response to beta-adrenergic agonists
Table 2) (8). Similar to work in isolated myocytes, devel-
ped tension in response to beta-adrenergic stimulation in
solated trabecular muscle preparations was also improved
13) (Fig. 1). Basal relaxation was also improved in myo-
Contractile Characteristics Are Improvedin Myo yt s After Support With an LVADTable 1 Contractile Characteristics Are Improvedin Myocytes After Support With an LVAD
Contractile Characteristic
HF Monocytes
(n  57)
HF LVAD Monocytes
(n  35)
Magnitude of shortening (% RCL) 6.9 0.5 9.6 0.7*
Time to peak contraction (s) 0.75 0.04 0.37 0.01
Time to 50% relaxation (s) 1.45 0.11 0.55 0.02
*Significant difference between the HF and the HF LVAD monocytes at p  0.05. Adapted from
Dipla et al. (8).
HF  heart failure; LVAD  left ventricular assist device; RCL  resting cell length.
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February 8, 2011:641–52 LVAD Review: Clinical, Molecular, and Genomiccytes after LVAD support (Table 2) (8). However, relax-
ation in response to isoproterenol was not improved
(Table 2) (8). This was confirmed in isolated trabecular
preparations in a separate study (Fig. 1) (13). Figure 1 also
hows the significant magnitude in maximal rates of devel-
ped rise and fall in tension in response to the beta agonist
soproterenol. Significant improvements are seen in both
ise and fall in tension with LVADs compared with failing
earts. In sum, these findings suggest that LVAD support
mproves developed tension and relaxation rates at rest and
lso improves developed tension in response to beta agonists.
owever, LVAD support did not improve relaxation rates
fter stimulation with beta agonists.
eta-adrenergic signaling. Improvements in developed
ension with LVADs have been shown to be accompanied
y increased beta-adrenergic receptor density (13,16). Early
Isoproterenol Response on Contractile ParametTable 2 Isoproterenol Response on Contrac
Contractile Parameter Disease Group
Magnitude of shortening (% RCL) HF
HF-VAD
Time to 50% relaxation (s) HF
HF-VAD
*Significant difference (p 0.0125) between baseline and isoprotere
myocytes on the delta scores (t test for independent samples). ‡Sign
independent samples). Reproduced, with permission, from Dipla et al
HF  heart failure; RCL  resting cell length; VAD  ventricular as
Figure 1 Response of Muscles to 1 mol/l Isoproterenol
Muscles from nonfailing hearts (NF), failing hearts without left ventricular assist d
(TPT); (B) time to half relaxation (THR); (C) maximal rate of tension rise (dT/dt);
contraction (mean  SEM). This study shows no change in TPT (A) or THR (B) be
in dT/dt (C) and dT/dt (D) were seen in the failing hearts that were improved
Adapted from Ogletree-Hughes et al. (13).tudies showed that beta-adrenergic density was improved
ith LVAD therapy in 17 patients compared with 8
onfailing patients (13). A recent study confirmed these
ndings (15) (Fig. 2). Whether this improvement in
eta-adrenergic density translates to intermediate bio-
hemical improvements in the beta-adrenergic signaling
athway that are associated with improved developed
ension are not known. It is possible that other molecules
n the signaling pathway may still be “desensitized” that
ontrol the “brake” on this important pathway that
egulates myocyte contractility and remodeling.
eta-adrenergic signaling in recovery patients. More re-
ent work assessed beta-adrenergic signaling pathways in an
nbiased analysis using a gene chip platform in 6 paired
eart samples from patients who achieved sufficient myo-
ardial recovery to allow explantation of the devices (17,18).
arameters
Baseline Isoproterenol Delta Score
6.43 0.73 8.92 0.78* 2.49 0.58†
7.63 0.88 12.56 1.01*‡ 4.93 1.42
1.28 0.19 0.95 0.16 0.32 0.15
0.70 0.07‡ 0.53 0.03 0.17 0.08
red t test). †Significant difference (p 0.05) between HF and HF-VAD
ifference (p  0.0125) between HF and HF-VAD myocytes (t test for
ice.
LVAD) support, and failing hearts with LVAD support. (A) Time to peak tension
aximal rate of tension fall (dT/dt). Data are shown as change from baseline
NF, failing hearts, and failing hearts with LVAD support. Significant decreases
VAD support. n  number of muscles/number of hearts. *p  0.05 versus NF.erstile P
nol (pai
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LVAD Review: Clinical, Molecular, and Genomic February 8, 2011:641–52A novel combination therapy consisting of an LVAD
combined with pharmacologic therapy including the selec-
tive beta-2 agonist clenbuterol has shown promise in restor-
ing ventricular function in patients with heart failure (17).
The aim of this study was to identify common genes and
signaling pathways whose expression was associated with
reversal of heart failure and restoration of ventricular func-
tion. Microarray analysis was performed on 6 paired human
heart samples harvested at the time of LVAD implantation
and at the time of LVAD explantation for recovery of
ventricular function. Follow-up data showed that the im-
provements in ventricular function were maintained for
more than 5 years after explantation. This dataset represents
the first description of signaling pathways associated with
the functional recovery of end-stage human heart failure
and the identification of new targets in the human heart that
are modified by this combination therapy. Analyzing the
gene expression profiles from these patients at the time of
LVAD explantation compared with LVAD implantation
(heart failure) resulted in the identification of pathways
significantly enriched with genes whose expression was
statistically different between heart failure and recovery.
Instead of a gene-by-gene approach, this study used a
network analysis, with the goal of identifying pathways that
are altered in the process of recovery from heart failure (18).
Put simply, gene lists are imported into the Ingenuity
database (Ingenuity Systems, Inc., Redwood City, Califor-
nia), and the program subsequently overlays these genes into
several described networks to identify the best overall fit. As
seen in Figure 3, significant changes in genes in the
Figure 2
Density of Beta-Adrenergic Receptors
in LV and RV Myocardial Samples of NF,
Medically Managed, and LVAD-Supported Hearts
Data are reported as mean  SD of maximal binding (Bmax) values determined
from Scatchard transformation of saturated binding data. HF  heart failure
(medically managed); LV  left ventricular; LVAD  left ventricular assist
device; NF  nonfailing; RV  right ventricular. *p  0.01 versus nonfailing
and LVAD-supported hearts. Adapted from Klotz et al. (15).beta-adrenergic signaling pathway in recovered hearts in-cluded Rap guanine nucleotide exchange factor 4 (exchange
protein directly activated by cyclic adenosine monophos-
phate 2 [Epac2], down-regulated at explantation 2.2-fold),
protein kinase, regulatory subunit, type I alpha (down-
regulated at explantation 1.5-fold), phosphodiesterase 1A
(down-regulated at explantation 1.5-fold), phosphodiester-
ase 3B (down-regulated 1.5-fold), and calcineurin A (up-
regulated 1.4-fold) (18). The down-regulation in Epac2 was
unique to the recovered group and confirmed in a replica-
tion cohort, suggesting that this target may be important for
recovery. (This target is discussed again in the following
section on calcium handling.) It is important to keep in
mind that expression changes in messenger ribonucleic acid
(mRNA) need to translate to functional changes in bio-
chemical signaling to be causally related to functional
recovery. Studies of this nature will be critical for moving
the field forward.
Calcium handling. Impaired myocardial relaxation is a
physiologic characteristic of heart failure. The reported
improvements in basal relaxation rate with LVADs have not
been definitively linked to changes in calcium handling.
Elegant functional experiments have been carried out to
assess calcium transients and expression of calcium handling
proteins (7,19). In a study by Chaudhary et al. (7), LVAD-
supported failing myocytes exhibited faster decay in both
early and late stages of the [Ca2]i transient compared with
yocytes from failing hearts not supported with LVADs.
hese same findings were seen in patients who recovered.
n increase in ribonucleic acid (RNA) expression of the
a-Ca2 exchanger was identified in this study from
ecovered patients (19). In the study with nonrecovered
atients, changes were not measured at the RNA level, and
o changes were detected at the protein level of the
a-Ca2 exchanger (7), thus not offering an explanation
for the faster decay times in the [Ca2]i transients (20,21).
summary of calcium handling changes in response to an
VAD is shown in Figure 4.
alcium handling in recovery patients. Expanding on
hese findings, recent work by Terracciano et al. (26)
howed the largest improvements in action potential dura-
ion and sarcoplasmic reticulum calcium content in patients
ho achieved clinical recovery in response to LVADs and
harmacological therapy (Fig. 5) (Harefield Recovery Pro-
ocol Study). These findings help distinguish contractile and
olecular differences in myocytes from hearts that achieve
linical recovery compared with those that achieve partial
ecovery (26). Another recent study by Ogletree et al. (27)
emonstrated that the benefits of unloading on calcium
andling and contractility are time dependent. Patients
ith shorter durations of support (115 days) achieved
ignificant increases in sarco/endoplasmic reticulum Ca2-
adenosine triphosphatase expression levels and correspond-
ing increases in developed tension (27). These improve-
ments, however, reverted back to failing levels in the
patients with longer durations of support (Fig. 6) (27). The
reason these changes are not persistent is unknown, but it
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February 8, 2011:641–52 LVAD Review: Clinical, Molecular, and Genomiccould be an indication of adverse remodeling signals with
prolonged unloading.
A recent phase II clinical trial, the CUPID (Calcium
Upregulation by Percutaneous Administration of Gene Ther-
apy in Cardiac Disease) study, is already testing sarco/
endoplasmic reticulum Ca2-adenosine triphosphatase 2a
ene therapy in patients with end-stage heart failure, with
ome initial indications of efficacy (28). A second potential
arget for drug development may be Epac2. Significant de-
reases in the calcium-regulating gene Epac2 were identified
fter LVAD support in 11 recovered hearts (Fig. 7) (18). This
Figure 3 Identification of Genes in the cAMP-Mediated Signalin
Whose Expression Was Altered in Association With R
Shaded symbols represent genes whose expression was significantly altered in execrease in Epac2 was unique to recovered hearts, as the battern was not found in nonrecovered hearts (Fig. 7) (18).
pac2 tethers cyclic adenosine monophosphate to mitogen-
ctivated protein kinase, calcium-mediated signaling through
uclear factor of activated T cells, and metabolic signaling
athways. The roles of both Epac2 and exchange protein
irectly activated by cyclic adenosine monophosphate 1 in
ultiple cell types and tissues, including the heart, nerves, and
ancreas, are just beginning to be understood (20,21).
ytoskeletal proteins and integrins in recovery patients.
yocardial recovery has also been associated with a specific
attern of changes in sarcomeric, nonsarcomeric, and mem-
thway
ery
d versus implanted samples (18). cAMP  cyclic adenosine monophosphate.g Pa
ecov
planterane-associated proteins (29). These changes are high-
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LVAD Review: Clinical, Molecular, and Genomic February 8, 2011:641–52lighted in Figure 8 (30). Affymetrix (Santa Clara, Califor-
ia) microarray analysis was performed on paired samples
before and after LVAD implantation) and analyzed with
eference to sarcomeric and nonsarcomeric cytoskeletal
roteins (29). In the recovery group, of the nonsarcom-
ric proteins, lamin A/C and spectrin increased from
efore to after LVAD implantation (29). The sarcomeric
roteins beta-actin, alpha-tropomyosin, alpha-1-actinin,
nd alpha-filamin A increased in the recovered group,
hile troponin T3 and alpha-2-actinin decreased at
xplantation (29). Vinculin decreased after LVAD sup-
ort in the recovered group but increased in the nonre-
overed group (29). Further work is needed in this area to
efine if these changes that occur in expression of cytoskel-
tal proteins and are uniquely associated with recovery are
ntegral to promoting improvements in contractility that are
ecessary for recovery.
Integrins are bidirectional signaling molecules and play a
Figure 4 Calcium Handling After LVAD Support
This figure summarizes work to date in the literature of ventricular assist devices.
assist device; NCX  Na-Ca2 exchanger; SERCA  sarco/endoplasmic reticulum
(2)  Terracciano et al. (26); (3)  Chen et al. (22); (4)  Marx et al. (23); (5)  Terr
(25); (9)  Heerdt et al. (10); (10)  Terracciano et al. (19).ole in mechanotransduction by mediating mechanical Fstretch) signals from the extracellular matrix, via protein
inase cascades that provoke changes in gene expression,
ncluding those involved in the hypertrophic response. Data
uggest that the integrin pathway may play a key role at the
olecular and cellular levels in processes of reverse remod-
ling and subsequent functional recovery occurring in
hese patients (29). Work in a pre-clinical rat model has
hown similar findings (31). Online Figure 1 summarizes
he changes in the integrin signaling pathway along with
he cytoskeletal proteins that occurred in the recovery
ohort (29).
etabolism and growth factor–related genes and signaling
athways in recovery patients. In addition to the finding
hat the process of recovery was associated with cyclic
denosine monophosphate, calcium handling genes, and
1
ted, with permission, from Terracciano et al. (19)1. LVAD  left ventricular
-adenosine triphosphatase; SR  sarcoplasmic reticulum; (1)  Harding et al. (9);
o et al. (24); (6)  Dipla et al. (8); (7)  Chaudhary et al. (7); (8)  Frazier et al.Reprin
Ca2
accianThe original online posting of this article did not correctly identify the source of
igure 4. This has now been corrected.
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February 8, 2011:641–52 LVAD Review: Clinical, Molecular, and Genomicintegrin signaling, several new targets were identified in an
unbiased approach, including those that regulate metabo-
lism. Arginine:glycine amidinotransferase (AGAT), a rate-
limiting enzyme in the creatine synthesis pathway, was
significantly down-regulated after unloading in the recov-
ered hearts, returning to normal levels in direct contrast to
the up-regulation of AGAT in patients with heart failure
compared with donor hearts (18,32). These changes in
AGAT mRNA levels suggest a response to heart failure that
involves elevated local creatine synthesis (18,32). The mech-
anisms leading to induced AGAT expression are unknown
but may be a response to the depletion of the local creatine
pool, which we and others have shown to be a feature of
heart failure.
Insulin growth factor (IGF)-I mRNA was elevated at the
time of LVAD explantation in the patients who received
pharmacologic therapy, which included clenbuterol (33).
There were 2 groups distinguishable, those with low IGF-I
mRNA at implantation who showed significant increase
during recovery and those with high IGF-I mRNA at
implantation who remained high (33). IGF-I levels corre-
lated with stromal cell–derived factor mRNA measured
both in LVAD patients and in a wider cohort of patients
with heart failure (33). Microarray analysis of implantation
and explantation samples of recovery patients further re-
Figure 5
SR Calcium Content From Myocytes Isolated From
LVAD Cores and Tissue From Explanted (Recovery)
and Transplanted Hearts Without Recovery
LVAD  left ventricular assist device; SR  sarcoplasmic reticulum.
Reprinted, with permission, from Terracciano et al. (26).vealed elevated IGF-II and IGF binding protein-4 and IGFbinding protein-6. IGF-I may act to limit atrophy and
apoptosis during reverse remodeling and to promote repair
and regeneration in concert with stromal cell–derived fac-
tor. It may have important effects on fibroblasts (33). A
previous analysis in 19 paired patient samples before and
after LVAD support with the HeartMate XVE device in a
cohort of patients who were transplanted (did not achieve
full recovery) revealed expression changes in the Forkhead
transcription factor family and genes governing the angio-
tensin/insulin signaling axis (34). This analysis also identi-
fied a significant correlation in expression between Fork-
head box 03A and angiotensin II type 1 receptor (34). More
Figure 6 Developed Tension, Expressed
as Percent Change From Baseline
(A) Stimulation delay–response curves at delay periods ranging from 2 to
120 s (n  number of muscles/number of hearts). (B) Data from the 40-s
delay period. Right: separation of left ventricular assist device (LVAD)–sup-
ported failing hearts (FLVAD) by duration of LVAD support. Short duration  7
to 103 days; long duration  127 to 334 days. (C) Relationship between dura-
tion and post-rest potentiation recovery (p  0.05) at 40-s delay in hearts with
LVADs, by heart. *p  0.05 versus NF. Adapted from Ogletree et al. (27).
F  failing hearts; NF  nonfailing hearts.
648 Hall et al. JACC Vol. 57, No. 6, 2011
LVAD Review: Clinical, Molecular, and Genomic February 8, 2011:641–52work will need to be done to determine the role and
integration of IGF-I/Forkhead and angiotensin II in re-
modeling and recovery and localize these signals to myo-
cytes and/or fibroblasts. In a later section, we discuss
maladaptive fibrotic remodeling in response to LVADs and
the potential role of angiotensin-converting enzyme (ACE)
inhibition in alleviating ventricular stiffness and fibrosis. A
Figure 7 Epac2 mRNA Levels
(A) Exchange protein directly activated by cyclic adenosine monophosphate 2 (Epa
recovered hearts after ventricular assist device support (n  11, p  0.01). (B) N
Figure 8 Changes in the Cytoskeletal Pathway That Occurred i
Reproduced, with permission, from Birks et al. (29), adapted from Towbin and Bowrecent study by Bhavsar et al. (35) showed that IGF-I is
released preferentially from fibroblasts over cardiac myo-
cytes. Thus, the interaction between angiotensin II and
IGF-I both mechanistically and clinically is still not well
understood.
Micro-ribonucleic acid (miRNA). miRNAs constitute
one of the more abundant classes of molecules that
essenger ribonucleic acid (mRNA) levels were significantly reduced in
ificant differences were seen in nonrecovered hearts. (n  5, p  NS) (18).
covered Patients Only
0).c2) m
o signn Re
les (3
of devi
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nous, noncoding RNAs (36). Many of these miRNAs
have been shown to inhibit post-transcriptional process-
ing (36,37). Recent work by Matkovich et al. (38)
suggests that adding miRNA profiling to mRNA profil-
ing enhances the ability of mRNA profiles to categorize
the clinical status of heart failure before and after
biomechanical unloading. The results of this study by
Matkovich et al. (38) confirmed 3 earlier identified
miRNAs associated with heart failure (miR-24, miR-
125b, and miR-195) (38,39). In addition, Matkovich et
al. (38) extended earlier work in mouse models (39,40)
showing that miR-21, miR-23a, and miR-199a-3p were
also regulated in human heart failure. One of the most
exciting aspects of the study by Matkovich et al. (38) was
the reversibility of the miRNAs with LVAD support.
Table 3 lists miRNAs that normalize after LVAD
support. It is not yet known which miRNA expression
changes are associated with clinical end points that
correlate with recovery.
Natriuretic peptides and chromogranin A are normalized
by LVAD support. Despite divergent etiologies, heart
failure is characterized by the activation of neurohormonal
systems: catecholamines, natriuretic peptides, and compo-
nents of the renin-angiotensin axis are increased and have
been found to have pathophysiological and prognostic
implications. Some of these molecules exert local paracrine
activation, but their plasma levels have been demonstrated
to be markers of clinical outcomes. Increased cardiac atrial
natriuretic peptide (ANP) and B-type natriuretic peptide
(BNP) expression in patients with heart failure is associated
with increased expression of the natriuretic peptides metab-
olizing natriuretic peptide receptor C receptors and blunted
responsiveness of guanylate cyclase A to ANP by reduced
cyclic guanosine monophosphate synthesis.
Unloading the failing heart with an LVAD is associated
with a decrease in natriuretic peptides and re-establishment
of the local responsiveness of guanylate cyclase A to ANP
(41). Cardiac expression of ANP, BNP, and natriuretic
peptide receptor C mRNA also correlated significantly with
MiRNAs That Normalize After LVAD SupportTable 3 MiRNAs That Normalize After LVAD Support
Fold Change
Name
Failing vs.
Nonfailing
Post-LVAD vs.
Nonfailing
Post-LV
Fai
miR-27b 3.15 1.14 4
miR-30a-5p 3.06 1.07 2
miR-30c 3.31 1.32 2
miR-30d 2.96 1.23 2
miR-103 3.54 1.20 2
miR-130a 3.06 1.36 2
miR-378 3.60 1.20 3
let-7f 4.84 1.18 4
n  10 LVAD-supported hearts, 80% men, 40% ischemic, average support time 1.7 months, type
LVAD  left ventricular assist device; miRNA  micro–ribonucleic acid.cardiomyocyte diameters. In contrast to the latter, the levelsof the natriuretic peptides are fully reversed to the level of
the controls, indicating that their expression is partly inde-
pendent of cardiac hypertrophy and regulated by heart
failure–associated factors such as cardiomyocyte stretch
(41). Evidence that unloading may be sufficient for a
decrease in natriuretic peptides (and that recovery is not
necessary) comes from pre-clinical data, in which natriuretic
peptides are decreased in heterotopic transplants of failing
rat hearts (42,43).
Chromogranin A is an acidic calcium-binding protein
and is the major soluble constituent in secretory vesicles
throughout the neuroendocrine system. Chromogranin A
was found to be significantly up-regulated during heart
failure and is co-stored with catecholamines and natriuretic
peptides. BNP and chromogranin A are co-stored in the
myocardium of patients with dilated cardiomyopathy,
whereas this colocalization was not found in healthy con-
trols (44). Wohlschlaeger et al. (45) investigated the expres-
sion of natriuretic peptides and chromogranin A by immu-
nohistochemistry and morphometric quantification before
and after LVAD implantation. In a different set of patients,
chromogranin A was evaluated in the plasma (45). We
demonstrated that in line with ANP and BNP, chromo-
granin A is significantly increased in patients with conges-
tive heart failure compared with healthy controls and decreased
by ventricular support (45). Moreover, sarcoplasmic colocaliza-
tion of BNP and chromogranin A is diminished after unload-
ing. However, because of its low expression, the negative
regulation of chromogranin A is not reflected by plasma levels,
so chromogranin A does not appear to be an appropriate
biomarker for the monitoring of “reverse cardiac remodeling”
after unloading (45) (Online Fig. 2).
Summary
In summary, left ventricular unloading in patients with
end-stage heart failure on LVAD support has been shown
to improve myocardial structure and function, including
improving beta-adrenergic responsiveness and myocyte con-
p Value
. Failing vs.
Nonfailing
Post-LVAD vs.
Nonfailing
Post-LVAD vs.
Failing
2.60 104 0.270 0.0620
4.76 104 0.566 0.0821
1.24 104 0.105 0.0853
6.47 104 0.211 0.116
1.24 104 0.156 0.0834
6.80 104 0.127 0.270
6.25 104 0.153 0.0544
1.50 104 0.211 0.00543
ce not disclosed. Reproduced, with permission, from Matkovich et al. (38).AD vs
ling
.75
.85
.51
.40
.94
.26
.00
.11tractility. The phenotypic changes in the heart associated
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miRNA, or post-translational mechanisms such as ubiquiti-
nation or phosphorylation events, as discussed by Margulies
(11). Several working groups, including our own, have
defined changes in gene expression that occur with LVAD
support that may be important in improving beta-
adrenergic responsiveness and calcium handling, including
partial restoration of beta-receptor density and altered
regulation of the genes in G-protein–coupled signaling and
calcium handling. A gene expression profile analysis using
gene chips with 199 myocardial samples from failing,
LVAD-supported and nonfailing human hearts demon-
strated that the majority of transcriptional changes accom-
panying morphological and functional alterations in the
heart were modest (46). Changes in miRNA expression in a
recent study were more robust (38). Protein expression has
been mainly restricted to calcium handling, beta-adrenergic,
and extracellular matrix pathways, and much work is yet to
be done. Pairing pre-clinical work in model organisms in
which these targets (genes or miRNA) are overexpressed or
deleted and their function is understood in the context of
heart failure will be helpful. Overexpressing genes in which
phosphorylation sites (or other site of post-translational
modification) are mutated will aid in the identification of
how post-translational mechanisms regulate myocardial
function and remodeling. However, rodent models do not
recapitulate human heart failure. Secondly, heterotopic
transplantation has limitations in modeling assist devices.
The next generation of studies will take advantage of
state-of-the-art technology to yield more information from
human myocytes from core biopsies and define how changes in
RNA and protein may alter morphology and contractility.
A recent histological study by Drakos et al. (47) found
that unloading with LVADs in 15 patients receiving the
HeartMate I device (pulsatile) resulted in a 33% increase in
microvascular density, although the total luminal area was
decreased, so the functional patency of these vessels is
unclear.
Some remodeling responses to mechanical unloading may
be maladaptive. The most prominent advancement of this
hypothesis is the concept of myocardial atrophy and rever-
sal, which is being investigated in the Harefield Recovery
Protocol Studies described earlier. Mechanisms regulating
cardiac atrophy are unknown, although it is thought that the
ubiquitin-proteasome degradation pathway that is active in
skeletal muscle and the coronary vascular bed plays a role
and may represent an overcompensation because of the lack
of opposing hypertrophic stimuli after chronic unloading
(48,49). Another concept in maladaptive remodeling is that
of fibrosis and extracellular matrix turnover. One study by
Klotz et al. (50) of collagen content and subtypes after
LVAD support found a significant increase in total and
cross-linked collagen in the myocardium compared with
nonfailing and medically managed patients with heart fail-
ure, which correlated with increased left ventricular stiffness.
Interestingly, the majority of LVAD patients after implan-tation were not on ACE inhibitors, which have been
demonstrated to improve fibrosis and remodeling (51,52). A
subsequent retrospective cohort study by the same group,
comparing LVAD patients who did and did not receive
ACE inhibitor therapy after implantation, demonstrated a
significant decrease in collagen content and myocardial
stiffness in the cohort with LVADs plus ACE inhibitors
(16). At the molecular level, quantitation of matrix metal-
loproteinases and their inhibitors demonstrated near nor-
malization of the ratio of matrix metalloproteinase 1 to
tissue inhibitor of metalloproteinase 1 in LVAD patients
receiving ACE inhibitors, suggesting a mechanism for the
improvement collagen turnover. These findings support the
hypothesis that maximizing optimal medical management
after ventricular unloading with LVADs may promote
myocardial recovery. In sum, the modest gene expression
changes are sufficient to change vascular and fibrotic prop-
erties in the heart. However, a more thorough understand-
ing of the unique therapies and underlying genetic and
environmental properties will further aid in our understand-
ing of the biological pathways through which unloading
with LVADs leads to remodeling and recovery. A better
understanding of the biology may allow us to alter the
engineering properties of the devices and/or patient selec-
tion criteria (see the following discussion) to improve
outcomes.
Study limitations. The LVAD population presents a
unique and valuable opportunity to obtain myocardial tissue
of patients with end-stage heart failure at the time of
implantation, and often at the time of heart and/or LVAD
explantation, after a period of unloading. There are, how-
ever, some recognized limitations of carrying out molecular
studies on the LVAD patient population. Study sizes tend
to be small, which is a particular challenge when performing
large-scale transcriptome analysis, although this limitation
is being overcome by multicenter collaborations and the
overall increase in the use of LVADs. Tissue procurement
must also be carefully planned, and the tissue received from
the apical transmural tissue core may be fibrotic and not
representative of the whole myocardium. In addition, the
clinical presentation, duration of support, and medical
management are uncontrollable variables, creating a heter-
ogenous patient population. Animal models have been
created in an attempt to study ventricular unloading in a
more controlled fashion. These include a thoracic inferior
vena cava constriction model described by Lisy et al.
(53,54), which demonstrates myocardial atrophy with
chronic unloading, with significant up-regulation of the
renin-angiotensin-aldosterone system axis and decrease in
ANP and BNP expression. Although the myocardial atro-
phy findings have important implications for research in
human LVAD patients, this model creates a biventricular
low cardiac output state from a presumably normal baseline
and thus is not analogous to the physiologic effect of
implanting an LVAD. Another established animal model is
that of heterotopic cardiac transplantation, described by
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model, heart failure is induced in a “donor” cohort of
rabbits, after which the hearts are transplanted heterotopi-
cally by anastomosing the aorta and pulmonary trunk to the
recipient rabbits’ carotid artery and internal jugular vein,
respectively. The heart is perfused only through the coro-
nary circulation, through the coronary sinus, and returned to
the recipient via the right heart, creating a completely
unloaded left ventricle (55). Although this model is also
intriguing, it also involves a transplantation, removing the
organ from the systemic physiology of the heart failure
“donor,” and also subjecting the heart to the immunological
and biochemical milieu associated with transplantation.
Given the limitations of animal models, it is critical to
continue advancing translational research in the LVAD
patient population to apply the understanding of unloading
responses in heart failure to the development of clinical
predictors and medical therapy for these patients.
Final clinical perspective and future directions. Recent
clinical trials have shown that both pulsatile and
continuous-flow LVADs significantly improve the quality
of life and functional capacity of patients with heart failure
(4,5). Translational research in the area of LVAD support
has provided new information on signaling pathways. Tis-
sue procurement, deoxyribonucleic acid sequencing, RNA
sequencing, and epigenetic tools will help in our further
understanding of the underlying signals regulating the
reverse remodeling and recovery potential of the failing
human heart. Investigation in the LVAD patient popula-
tion has been limited by the fact that there is no consensus
on medical management toward, and clinical monitoring of,
myocardial recovery. For instance, the findings correlating
ACE inhibitor use and favorable decrease in myocardial
stiffness and collagen subtypes suggest a greater role for
continuing optimal medical management after LVAD
placement. The elucidation of myocardial atrophy pathways
may also illuminate the concept of optimizing or weaning
unloading after LVAD placement to minimize atrophy and
promote recovery. Our current understanding of the role of
extracellular matrix in heart failure and the ability of the
fibroblast to remodel in response to LVADs represents a
new focus area. Further elucidating these pathways will
allow for the discovery of novel therapeutic strategies for
patients in earlier stages of heart failure. Identification of the
biomarkers and factors that will aid in risk stratification for
patients with LVAD therapy will help move this field
forward and enhance patient care.
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